Shares of United Therapeutics Corporation (NASDAQ:UTHR) jumped more than 13% on Monday morning following the announcement of positive topline results from the Phase 3 TETON‑1 trial of its inhaled therapy, Tyvaso, in idiopathic pulmonary fibrosis (IPF).
Jefferies analysts called the results “highly clinically meaningful,” noting that the trial met its primary endpoint with a change in absolute forced vital capacity (FVC) of 130.1 milliliters at week 52 compared with placebo (p<0.0001), even exceeding the improvement seen in the earlier TETON‑2 study.
“With two overwhelmingly positive Phase 3 trials, the company plans to submit a supplemental New Drug Application by summer 2026,” Jefferies wrote. “We see a high probability of approval and potential for Tyvaso to become the new standard of care in IPF.”
The integrated analysis of TETON‑1 and TETON‑2 showed an FVC improvement of 111.8 milliliters, further supporting the therapy’s efficacy across patient subgroups, including those receiving background antifibrotic treatment, varying smoking status, and supplemental oxygen. Secondary endpoints, including time to first clinical worsening event, also showed statistically significant improvements, while overall survival at week 52 favored Tyvaso without reaching statistical significance.
Analysts highlighted Tyvaso’s potential to differentiate in a market with few approved therapies. Currently, only two drugs are approved for IPF and one for progressive pulmonary fibrosis, all of which are oral treatments. Tyvaso, delivered via inhalation, could offer higher lung exposure at lower doses, potentially improving efficacy and reducing systemic side effects.
Jefferies added that investors could see a 15 to 25% stock move as market assumptions on approval probability and potential market penetration are updated. They estimated the IPF market opportunity for Tyvaso could reach $5 to 10 billion, whether used as monotherapy or in combination with existing standard-of-care treatments.
Detailed data from TETON‑1 is expected to be presented at the American Thoracic Society’s annual meeting in May in Orlando. Analysts said the TETON‑1 topline results confirm the TETON‑2 findings were reproducible and shift the focus to how quickly and widely Tyvaso could be adopted.
Shares of United Therapeutics had reached around $591 on Monday morning.